Cytek Biosciences, Inc. (CTKB) vs Design Therapeutics, Inc. (DSGN)
A side-by-side comparison of Cytek Biosciences, Inc. and Design Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTKB
Cytek Biosciences, Inc.
$5.98HealthcareDelayed quote: Oct 6, 2026, 10:00 AM EDT
DSGN
Design Therapeutics, Inc.
$12.16HealthcareDelayed quote: Oct 6, 2026, 10:00 AM EDT
Total return — CTKB vs DSGN
growth of $100 · dividends reinvested · last 5yCTKB -67.5% (-20.1%/yr)DSGN -32.1% (-7.4%/yr)DSGN compounded faster over this window
CTKB DSGN
CTKB vs DSGN: by the numbers
- •CTKB is the larger company ($772M vs $759M market cap).
- •Both run net losses; DSGN's is the smaller (0.00% vs -38.98% net margin).
Metrics side by side
Valuation
| Metric | CTKB | DSGN |
|---|---|---|
| P/S ratio | 3.74 | N/A |
| P/B ratio | 2.40 | 3.76 |
Profitability
| Metric | CTKB | DSGN |
|---|---|---|
| Gross margin | 53.23% | 0.00% |
| Operating margin | -21.60% | 0.00% |
| Net margin | -38.98% | 0.00% |
| ROE | -25.03% | -35.07% |
| ROIC | -12.00% | -38.92% |
Growth (annualized)
| Metric | CTKB | DSGN |
|---|---|---|
| Revenue CAGR (5Y) | 13.37% | N/A |
| Total return CAGR (5Y) | -23.16% | -3.82% |
Frequently asked
- How have CTKB and DSGN total returns compared?
- Over the past 5 years, CTKB delivered -23.16% and DSGN delivered -3.82% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.